Science and Research
RUBY: A Study to Evaluate the Clinical Safety and Efficacy of OKG-0301 in the Treatment of Acute Adenoviral Conjunctivitis
The purpose of the research is to test if the OKG-0301 can reduce the length of time patients are infectious with adenoviral conjunctivitis, as well as reducing common signs and symptoms such as eye redness and eye discharge.
Overview
The RUBY trial is a phase II, multi-centre, randomised, double masked, placebo-controlled, clinical trial of the study drug OKG-0301 in adenoviral conjunctivitis patients.
The purpose of the research is to test if the OKG-0301 can reduce the length of time patients are infectious with adenoviral conjunctivitis, as well as reducing common signs and symptoms such as eye redness and eye discharge.
This is a short study where patients will be followed up for 4 visits over 14 days. Patients on the study will be randomised into one of three treatment groups: placebo (no medical benefit), OKG-0301 in 0.03% strength or OKG-0301 in 0.012% strength.
- Principal Investigator
Professor Mark Daniell
The RUBY trial is a phase II, multi-centre, randomised, double masked, placebo-controlled, clinical trial of the study drug OKG-0301 in adenoviral conjunctivitis patients.
The purpose of the research is to test if the OKG-0301 can reduce the length of time patients are infectious with adenoviral conjunctivitis, as well as reducing common signs and symptoms such as eye redness and eye discharge.
This is a short study where patients will be followed up for 4 visits over 14 days. Patients on the study will be randomised into one of three treatment groups: placebo (no medical benefit), OKG-0301 in 0.03% strength or OKG-0301 in 0.012% strength.
- Principal Investigator
Learn more
View this study at ClinicalTrials.gov
This international database listing provides more detailed information about this study.